BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24852117)

  • 1. BINGO: targeted therapy for advanced biliary-tract cancer.
    Valle JW
    Lancet Oncol; 2014 Jul; 15(8):778-80. PubMed ID: 24852117
    [No Abstract]   [Full Text] [Related]  

  • 2. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to move to targeted drugs in biliary tract cancer?
    Louvet C; Tournigand C
    Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
    Chang PY; Cheng MF; Lee HS; Hsieh CB; Yao NS
    Onkologie; 2010; 33(1-2):45-7. PubMed ID: 20164661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
    Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
    Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
    [No Abstract]   [Full Text] [Related]  

  • 6. Biliary Tract Cancers: Finding Better Ways to Lump and Split.
    Kelley RK; Bardeesy N
    J Clin Oncol; 2015 Aug; 33(24):2588-90. PubMed ID: 26195717
    [No Abstract]   [Full Text] [Related]  

  • 7. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
    Law LY
    J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
    Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
    Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.
    Yashima Y; Sato S; Kawai T; Sugimoto T; Sato T; Kanda M; Obi S
    Hepatol Int; 2015 Jan; 9(1):142-8. PubMed ID: 25788388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
    Subbiah IM; Subbiah V; Tsimberidou AM; Naing A; Kaseb AO; Javle M; Fu S; Hong DS; Piha-Paul S; Wheler JJ; Hess KR; Janku F; Falchook GS; Wolff RA; Kurzrock R
    Oncotarget; 2013 Jan; 4(1):156-65. PubMed ID: 23391555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for biliary tract cancers.
    Faris JE; Zhu AX
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial chemotherapy and conformal radiation abolish malignant biliary obstruction.
    Guan YS; Qing He ; Ping Li ; Fu YC; Zhao SW
    Integr Cancer Ther; 2008 Mar; 7(1):51-3. PubMed ID: 18292595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.
    Wang Z; Zeng T; Li Y; Zhang D; Yuan Z; Huang M; Yang Y; Zhou W
    Front Immunol; 2021; 12():799822. PubMed ID: 35003124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Regional chemotherapy in experimental cholangiocarcinoma in pigs].
    Dufek V; Petrtýl J
    Cas Lek Cesk; 1998 Aug; 137(15):464-6. PubMed ID: 9748745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
    Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
    Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Sporadic Case of Advanced Metastatic Cholangiocarcinoma in a Child: A Case Report and Review of Literature.
    Hall C; Mamlok V; Al-Khalil I
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e333-5. PubMed ID: 25851556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholangiocarcinoma.
    Squadroni M; Tondulli L; Gatta G; Mosconi S; Beretta G; Labianca R
    Crit Rev Oncol Hematol; 2017 Aug; 116():11-31. PubMed ID: 28693792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.